L

Lytix Biopharma AS
LYTIX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
NOK525.62M
EV
NOK428.01M
Shares Outstanding
68.26M
Beta
-0.44
Industry
Biotechnology

Wall Street View

Analyst Rating
NO_OPINION
Analyst Target Price
Number of Analysts
1
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Lytix Biopharma AS

gainify

L

Lytix Biopharma AS

LYTIX

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinic...

Sector

Healthcare

Industry

Biotechnology

CEO

Rekdal, Oystein

Employees

8

IPO Date

2021-06-14

Headquarters

Sandakerveien 138, Oslo, Oslo, 0484, Norway

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.